[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Patient on VV-ECMO with severe ARDS, suspected HIT (4T score 6), heparin discontinued, argatroban initiated, and significant hemolysis (plasma free hemoglobin 800 mg/dL). These clues indicate need for reliable argatroban monitoring unaffected by hemolysis, coagulopathy, or ECMO-related factors.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as uniquely best.\\nMain medical accuracy issue(s), if any: None; aligns with current standards where chromogenic anti-IIa assay directly measures argatroban's thrombin inhibition, least interfered by hemolysis or factor deficiencies in ECMO/HIT settings. aPTT is unreliable due to these interferences; anti-Xa targets different mechanism; ACT affected by platelets/fibrinogen; dRVVT irrelevant for DTI monitoring.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Patient on VV-ECMO with severe ARDS, suspected HIT (4T score 6), heparin discontinued, argatroban initiated, and significant hemolysis (plasma free hemoglobin 800 mg/dL). These clues indicate need for reliable argatroban monitoring unaffected by hemolysis, coagulopathy, or ECMO-related factors.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as uniquely best.\nMain medical accuracy issue(s), if any: None; aligns with current standards where chromogenic anti-IIa assay directly measures argatroban's thrombin inhibition, least interfered by hemolysis or factor deficiencies in ECMO/HIT settings. aPTT is unreliable due to these interferences; anti-Xa targets different mechanism; ACT affected by platelets/fibrinogen; dRVVT irrelevant for DTI monitoring.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic pancreatic adenocarcinoma treated with gemcitabine, acute kidney injury (creatinine 3.2 mg/dL), thrombocytopenia (45,000/µL), schistocytes, elevated LDH (2200 IU/L), low haptoglobin (<10 mg/dL), and ADAMTS13 activity of 35% (not severely deficient, excluding TTP). These point to gemcitabine-induced thrombotic microangiopathy (TMA), where the most appropriate initial management is drug discontinuation and supportive care. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., ADAMTS13 level rules out TTP, oncology context implicates gemcitabine) to identify C as the unique best option without contradictions or underspecification. Alternatives are inferior: A (plasma exchange) and D (rituximab) target TTP; B (eculizumab) addresses complement-mediated aHUS; E (caplacizumab) is for TTP. Main medical accuracy issue(s): None; aligns with current standards recognizing gemcitabine as a cause of drug-induced TMA, where ADAMTS13 >10% excludes TTP, and management prioritizes drug cessation over plasma exchange or targeted therapies. Minimal fix: No edit required as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic pancreatic adenocarcinoma treated with gemcitabine, acute kidney injury (creatinine 3.2 mg/dL), thrombocytopenia (45,000/µL), schistocytes, elevated LDH (2200 IU/L), low haptoglobin (<10 mg/dL), and ADAMTS13 activity of 35% (not severely deficient, excluding TTP). These point to gemcitabine-induced thrombotic microangiopathy (TMA), where the most appropriate initial management is drug discontinuation and supportive care. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., ADAMTS13 level rules out TTP, oncology context implicates gemcitabine) to identify C as the unique best option without contradictions or underspecification. Alternatives are inferior: A (plasma exchange) and D (rituximab) target TTP; B (eculizumab) addresses complement-mediated aHUS; E (caplacizumab) is for TTP. Main medical accuracy issue(s): None; aligns with current standards recognizing gemcitabine as a cause of drug-induced TMA, where ADAMTS13 >10% excludes TTP, and management prioritizes drug cessation over plasma exchange or targeted therapies. Minimal fix: No edit required as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Recent barium carbonate ingestion (2 hours), profuse vomiting/diarrhea, profound muscle weakness, severe hypokalemia (2.1 mEq/L), and ECG ST-segment depression. These point to barium toxicity's hallmark: hypokalemia from intracellular potassium shift due to K+ channel blockade, with GI symptoms from irritant effects. Elimination focuses on preventing absorption via precipitation.\\nMain logical issue(s), if any: None; stem provides sufficient clues for discriminating B as unique best (mechanism: intracellular shift via channel blockade; elimination: oral sodium sulfate), while alternatives mismatch primary pathophysiology or offer ineffective/inappropriate strategies.\\nMain medical accuracy issue(s), if any: None; aligns with established toxicology: barium blocks rectifying K+ channels, sequestering K+ intracellularly (not GI/renal loss primarily); sodium sulfate forms insoluble BaSO4 for GI decontamination if early, superior to HD due to barium's large Vd. IV K+ repletion is adjunctive but not elimination-focused. Consistent with current guidelines (e.g., tox textbooks like Goldfrank's).\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Recent barium carbonate ingestion (2 hours), profuse vomiting/diarrhea, profound muscle weakness, severe hypokalemia (2.1 mEq/L), and ECG ST-segment depression. These point to barium toxicity's hallmark: hypokalemia from intracellular potassium shift due to K+ channel blockade, with GI symptoms from irritant effects. Elimination focuses on preventing absorption via precipitation.\nMain logical issue(s), if any: None; stem provides sufficient clues for discriminating B as unique best (mechanism: intracellular shift via channel blockade; elimination: oral sodium sulfate), while alternatives mismatch primary pathophysiology or offer ineffective/inappropriate strategies.\nMain medical accuracy issue(s), if any: None; aligns with established toxicology: barium blocks rectifying K+ channels, sequestering K+ intracellularly (not GI/renal loss primarily); sodium sulfate forms insoluble BaSO4 for GI decontamination if early, superior to HD due to barium's large Vd. IV K+ repletion is adjunctive but not elimination-focused. Consistent with current guidelines (e.g., tox textbooks like Goldfrank's).\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (primary); U (secondary, as specificity is underspecified without context of mild case). Verdict on keyed answer: Miskeyed. The clinical problem asks for the most specific test to diagnose GAMT deficiency in an infant with intractable seizures, hypotonia, developmental regression, bilateral globus pallidus hyperintensities on MRI, and low plasma creatine—classic findings for creatine synthesis disorders, particularly GAMT. Key stem clues: symptoms and MRI suggest brain creatine deficiency; low plasma creatine supports diagnosis but doesn't specify GAMT without GAA levels or genetics. These drive toward confirmatory testing, but fail to uniquely favor CSF GAA over genetics without additional details like suspected mild phenotype where plasma GAA might be normal. Main logical issue: A unique best answer exists (D, GAMT gene sequencing, as it directly confirms the specific genetic defect with high specificity), but the key (C) mismatches it; question phrasing allows defending D as most specific for diagnosis, while C is a biomarker test. Secondary underspecification: lacks detail on case severity to justify why CSF is preferable over plasma or genetics. Main medical accuracy issue: Rationale inaccurately emphasizes CSF GAA as most specific/sensitive, confusing sensitivity (useful in mild cases) with specificity; standard care uses plasma/urine GAA for initial diagnosis and genetic sequencing for confirmation; CSF is invasive and not routine. Minimal fix: Change the keyed answer to D (GAMT gene sequencing) to align with confirmatory diagnostic standards.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (primary); U (secondary, as specificity is underspecified without context of mild case). Verdict on keyed answer: Miskeyed. The clinical problem asks for the most specific test to diagnose GAMT deficiency in an infant with intractable seizures, hypotonia, developmental regression, bilateral globus pallidus hyperintensities on MRI, and low plasma creatine—classic findings for creatine synthesis disorders, particularly GAMT. Key stem clues: symptoms and MRI suggest brain creatine deficiency; low plasma creatine supports diagnosis but doesn't specify GAMT without GAA levels or genetics. These drive toward confirmatory testing, but fail to uniquely favor CSF GAA over genetics without additional details like suspected mild phenotype where plasma GAA might be normal. Main logical issue: A unique best answer exists (D, GAMT gene sequencing, as it directly confirms the specific genetic defect with high specificity), but the key (C) mismatches it; question phrasing allows defending D as most specific for diagnosis, while C is a biomarker test. Secondary underspecification: lacks detail on case severity to justify why CSF is preferable over plasma or genetics. Main medical accuracy issue: Rationale inaccurately emphasizes CSF GAA as most specific/sensitive, confusing sensitivity (useful in mild cases) with specificity; standard care uses plasma/urine GAA for initial diagnosis and genetic sequencing for confirmation; CSF is invasive and not routine. Minimal fix: Change the keyed answer to D (GAMT gene sequencing) to align with confirmatory diagnostic standards.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, gait ataxia over 18 months, and mild CSF lymphocytic pleocytosis collectively point to anti-IgLON5 disease, distinguished by its sleep and bulbar predominance without typical paraneoplastic or limbic features. These discriminate against alternatives like anti-Hu (paraneoplastic sensory neuropathy), anti-NMDA (psychiatric/seizure-dominant), anti-LGI1 (faciobrachial dystonia, hyponatremia), and anti-GAD65 (stiff-person/cerebellar ataxia without prominent sleep issues).\\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details for a single best answer without contradictions or underspecification, aligning with the keyed choice C.\\nMain medical accuracy issue(s), if any: None; the presentation and pathological association (tau deposition in brainstem/hypothalamus for anti-IgLON5) are consistent with current neurological consensus, including poor immunotherapy response and tauopathy features, per major guidelines and literature (e.g., Neurology journals). No inaccuracies in implied logic or outdated elements.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, gait ataxia over 18 months, and mild CSF lymphocytic pleocytosis collectively point to anti-IgLON5 disease, distinguished by its sleep and bulbar predominance without typical paraneoplastic or limbic features. These discriminate against alternatives like anti-Hu (paraneoplastic sensory neuropathy), anti-NMDA (psychiatric/seizure-dominant), anti-LGI1 (faciobrachial dystonia, hyponatremia), and anti-GAD65 (stiff-person/cerebellar ataxia without prominent sleep issues).\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details for a single best answer without contradictions or underspecification, aligning with the keyed choice C.\nMain medical accuracy issue(s), if any: None; the presentation and pathological association (tau deposition in brainstem/hypothalamus for anti-IgLON5) are consistent with current neurological consensus, including poor immunotherapy response and tauopathy features, per major guidelines and literature (e.g., Neurology journals). No inaccuracies in implied logic or outdated elements.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: VV-ECMO context implies venous air embolism; sudden extensive air in circuit with pulselessness signals acute emergency requiring immediate circuit intervention to prevent further embolization. These clues prioritize stopping air propagation over positional changes, flow increases, CPR, or mode conversion.\\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating B as uniquely best—halts embolization, removes air—while alternatives are inferior (A for arterial emboli only; C worsens issue; D secondary; E irrelevant acutely).\\nMain medical accuracy issue(s), if any: None; aligns with ECLS guidelines (e.g., ELSO) for VV-ECMO air embolism: stop pump, clamp venous line, aspirate from post-oxygenator port (arterial outflow). Rationale correctly notes venous nature, making Durant's ineffective and flow increase harmful. Pulselessness justifies urgency but not primary CPR.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: VV-ECMO context implies venous air embolism; sudden extensive air in circuit with pulselessness signals acute emergency requiring immediate circuit intervention to prevent further embolization. These clues prioritize stopping air propagation over positional changes, flow increases, CPR, or mode conversion.\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating B as uniquely best—halts embolization, removes air—while alternatives are inferior (A for arterial emboli only; C worsens issue; D secondary; E irrelevant acutely).\nMain medical accuracy issue(s), if any: None; aligns with ECLS guidelines (e.g., ELSO) for VV-ECMO air embolism: stop pump, clamp venous line, aspirate from post-oxygenator port (arterial outflow). Rationale correctly notes venous nature, making Durant's ineffective and flow increase harmful. Pulselessness justifies urgency but not primary CPR.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 22-year-old with relapsed ALL post-axicabtagene ciloleucel (CAR-T) develops status epilepticus and cerebral edema on day 12, unresponsive to methylprednisolone 1 g/day for 3 days, indicating steroid-refractory ICANS. These findings (neurotoxicity post-CAR-T, steroid failure) point to need for alternative anti-inflammatory therapy targeting IL-1 pathway.\\nMain logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting B as unique best (anakinra for refractory ICANS) while alternatives are inferior (A: minimal benefit from escalation; C: IL-6 target ineffective for ICANS; D: not indicated; E: risks eliminating CAR-T cells).\\nMain medical accuracy issue(s), if any: None; aligns with ASTCT guidelines recommending anakinra for steroid-refractory ICANS, tocilizumab for CRS, and avoiding cyclophosphamide/plasma exchange. Teaching point is precise and board-relevant.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 22-year-old with relapsed ALL post-axicabtagene ciloleucel (CAR-T) develops status epilepticus and cerebral edema on day 12, unresponsive to methylprednisolone 1 g/day for 3 days, indicating steroid-refractory ICANS. These findings (neurotoxicity post-CAR-T, steroid failure) point to need for alternative anti-inflammatory therapy targeting IL-1 pathway.\nMain logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting B as unique best (anakinra for refractory ICANS) while alternatives are inferior (A: minimal benefit from escalation; C: IL-6 target ineffective for ICANS; D: not indicated; E: risks eliminating CAR-T cells).\nMain medical accuracy issue(s), if any: None; aligns with ASTCT guidelines recommending anakinra for steroid-refractory ICANS, tocilizumab for CRS, and avoiding cyclophosphamide/plasma exchange. Teaching point is precise and board-relevant.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g sustained-release verapamil, indicating severe calcium channel blocker (CCB) overdose, with HIET initiated; question asks for optimal insulin dosing and monitoring frequency. These clues point to high-dose insulin (1-10 units/kg/hr) to counter insulin resistance and enhance myocardial glucose uptake, with hourly glucose checks to maintain euglycemia via dextrose infusion. Main logical issue(s): none; stem provides sufficient details for discrimination without contradictions or underspecification, allowing B as uniquely defensible. Alternatives are inferior: A has insufficient dose and infrequent monitoring; C has low dose and irrelevant potassium focus; D exceeds standard max dose with wrong lactate monitoring; E has overlapping but suboptimal dose range with pH focus. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., Tox guidelines) for HIET in severe CCB toxicity, emphasizing supraphysiologic insulin (up to 10 units/kg/hr) and frequent glucose monitoring; no inaccuracies or outdated elements. Minimal fix: none needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g sustained-release verapamil, indicating severe calcium channel blocker (CCB) overdose, with HIET initiated; question asks for optimal insulin dosing and monitoring frequency. These clues point to high-dose insulin (1-10 units/kg/hr) to counter insulin resistance and enhance myocardial glucose uptake, with hourly glucose checks to maintain euglycemia via dextrose infusion. Main logical issue(s): none; stem provides sufficient details for discrimination without contradictions or underspecification, allowing B as uniquely defensible. Alternatives are inferior: A has insufficient dose and infrequent monitoring; C has low dose and irrelevant potassium focus; D exceeds standard max dose with wrong lactate monitoring; E has overlapping but suboptimal dose range with pH focus. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., Tox guidelines) for HIET in severe CCB toxicity, emphasizing supraphysiologic insulin (up to 10 units/kg/hr) and frequent glucose monitoring; no inaccuracies or outdated elements. Minimal fix: none needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe eczema, petechiae, recurrent otitis media, and thrombocytopenia (30,000/µL) with small platelet volume, classic for Wiskott-Aldrich syndrome (WAS), prompting the question for the most sensitive diagnostic test. These findings imply WAS due to WASP gene mutations causing absent/reduced protein expression, eczema, immunodeficiency, and microthrombocytopenia. The keyed answer D (WASP protein expression by flow cytometry) fits as it directly assesses functional protein absence in lymphocytes, offering high sensitivity (detects effects of mutations that sequencing might miss, like large deletions or intronic variants). Alternatives: A (WASP gene sequencing) is definitive but less sensitive for undetected variants; B (platelet-associated antibody testing) is irrelevant as WAS thrombocytopenia is not antibody-mediated; C (lymphocyte subset enumeration) shows variable, nonspecific changes; E (serum IgE and IgA levels) reveals elevated IgE and low IgA, but these are nonspecific findings. Main logical issue(s): None; stem allows clear discrimination of D as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., flow cytometry as sensitive screening for WAS protein defects, per immunology standards). Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe eczema, petechiae, recurrent otitis media, and thrombocytopenia (30,000/µL) with small platelet volume, classic for Wiskott-Aldrich syndrome (WAS), prompting the question for the most sensitive diagnostic test. These findings imply WAS due to WASP gene mutations causing absent/reduced protein expression, eczema, immunodeficiency, and microthrombocytopenia. The keyed answer D (WASP protein expression by flow cytometry) fits as it directly assesses functional protein absence in lymphocytes, offering high sensitivity (detects effects of mutations that sequencing might miss, like large deletions or intronic variants). Alternatives: A (WASP gene sequencing) is definitive but less sensitive for undetected variants; B (platelet-associated antibody testing) is irrelevant as WAS thrombocytopenia is not antibody-mediated; C (lymphocyte subset enumeration) shows variable, nonspecific changes; E (serum IgE and IgA levels) reveals elevated IgE and low IgA, but these are nonspecific findings. Main logical issue(s): None; stem allows clear discrimination of D as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., flow cytometry as sensitive screening for WAS protein defects, per immunology standards). Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old with progressive myoclonus epilepsy, cerebellar ataxia, visual loss over 3 years, and EEG generalized spike-wave discharges, consistent with Kufs disease (adult NCL); question seeks most specific diagnostic test. These symptoms align with NCL's hallmark features, discriminating toward tests identifying characteristic lipofuscin deposits. Option C (skin biopsy with electron microscopy) fits by revealing specific fingerprint profiles or granular osmiophilic deposits. Alternatives: A targets unrelated epilepsy genes (SCN1A, GABRG2), not CLN-specific; B uses PAS staining on brain biopsy, which is invasive and less specific for NCL inclusions (EM preferred); D is for CJD; E for autoimmune epilepsy. No main logical issues; stem allows unique selection of C as most specific, non-invasive test without contradictions or underspecification. Main medical accuracy issues: None; aligns with consensus that EM on skin biopsy is diagnostic for NCL, with genetic testing (e.g., CLN6/8) confirmatory but potentially negative in variants; rationale accurately notes invasiveness of brain biopsy and irrelevance of others. Minimal fix: Change option A to 'NCL gene panel (CLN6, CLN8, CTSF)' to heighten discrimination, ensuring it remains inferior due to potential false negatives in variant forms.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old with progressive myoclonus epilepsy, cerebellar ataxia, visual loss over 3 years, and EEG generalized spike-wave discharges, consistent with Kufs disease (adult NCL); question seeks most specific diagnostic test. These symptoms align with NCL's hallmark features, discriminating toward tests identifying characteristic lipofuscin deposits. Option C (skin biopsy with electron microscopy) fits by revealing specific fingerprint profiles or granular osmiophilic deposits. Alternatives: A targets unrelated epilepsy genes (SCN1A, GABRG2), not CLN-specific; B uses PAS staining on brain biopsy, which is invasive and less specific for NCL inclusions (EM preferred); D is for CJD; E for autoimmune epilepsy. No main logical issues; stem allows unique selection of C as most specific, non-invasive test without contradictions or underspecification. Main medical accuracy issues: None; aligns with consensus that EM on skin biopsy is diagnostic for NCL, with genetic testing (e.g., CLN6/8) confirmatory but potentially negative in variants; rationale accurately notes invasiveness of brain biopsy and irrelevance of others. Minimal fix: Change option A to 'NCL gene panel (CLN6, CLN8, CTSF)' to heighten discrimination, ensuring it remains inferior due to potential false negatives in variant forms.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]